Global Retinal Vein Occlusion Market 2014-2018
https://www.reportbuyer.com/product/2255167/Global-Retinal-Vein-Occlusion-Market-2014-2018.html
Advertisement
About Retinal Vein OcclusionRetinal vein occlusion is a medical condition where there is a blockage in the retinal veins. This blocks the flow of blood in the retina, which can damage the nerve cells of the eye and result in loss of vision. Retinal vein occlusion can occur as a result of a clot in a vein, especially if the veins of the eye are very narrow. The disease is likely to affect people who are already suffering from hypertension, diabetes mellitus, or hyperlipidaemia. Retinal vein occlusion is one of the most common causes of blindness after diabetic retinopathy. It is also one of the most common vascular disorders of the eye. Retinal vein occlusion can be broadly classified into two types, central retinal vein occlusion and branch retinal vein occlusion, with the latter being more frequent. Central retinal vein occlusion can be divided into two further subtypes, ischemic central retinal vein occlusion and non-ischemic central retinal vein occlusion.
Advertisement
TechNavio's analysts forecast the Global Retinal Vein Occlusion market will grow at a CAGR of 16.04 percent over the period 2013-2018.
Covered in this Report: This report covers the present scenario and the growth prospects of the Global Retinal Vein Occlusion market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various therapies used in the treatment of retinal vein occlusion.TechNavio's report, the Global Retinal Vein Occlusion Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Retinal Vein Occlusion market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions- Americas - EMEA - APAC
Key Vendors- Bayer AG- F. Hoffmann-La Roche Ltd.- Novartis AG- Regeneron Pharmaceuticals Inc.
Other Prominent Vendors
- Alimera Sciences- Bristol-Myers Squibb- NicOx- Santen Pharmaceutical Co.- Valeant Pharmaceuticals International
Key Market Driver- High Unmet Need - For a full, detailed list, view our report.
Key Market Challenge- Serious Adverse Side Effects - For a full, detailed list, view our report.
Key Market Trend- Introduction of Biologics- For a full, detailed list, view our report.
Key Questions Answered in this Report- What will the market size be in 2018 and what will the growth rate be?- What are the key market trends?- What is driving this market?- What are the challenges to market growth?- Who are the key vendors in this market space?- What are the market opportunities and threats faced by the key vendors?- What are the strengths and weaknesses of the key vendors?
01. Executive Summary02. List of Abbreviations03. Scope of the Report03.1 Market Overview03.2 Product OfferingsProduct Portfolio04. Market Research Methodology04.1 Market Research Process04.2 Research Methodology05. Introduction06. Market Landscape06.1 Market Overview06.2 Market Size and Forecast06.3 Five Forces Analysis07. Pipeline Portfolio08. Rate of Incidence and Prevalence09. Market Segmentation by Type of Therapy09.1.1 Biologics09.1.2 Corticosteroids10. Market Segmentation by Route of Administration10.1.1 Intravitreal10.1.2 Intravenous11. Market Segmentation by Dosage Forms11.1.1 Solutions11.1.2 Implant12. Geographical Segmentation13. Buying Criteria14. Market Growth Drivers15. Drivers and their Impact16. Market Challenges17. Impact of Drivers and Challenges18. Market Trends19. Trends and their Impact20. Vendor Landscape20.1 Competitive Scenario20.1.1 Key News20.1.2 Mergers and Acquisitions20.2 Market Share Analysis 201320.2.1 Other Prominent Vendors21. Key Vendor Analysis21.1 Bayer21.1.1 Key Facts21.1.2 Business Overview21.1.3 Business Segmentation21.1.4 Business Segmentation by Revenue 2012 and 201321.1.5 Sales by Geography21.1.6 Business Strategy21.1.7 Key Information21.1.8 SWOT Analysis21.1.9 Strengths21.1.10 Weaknesses21.1.11 Opportunities21.1.12 Threats21.2 Roche21.2.1 Key Facts21.2.2 Business Overview21.2.3 Business Segmentation21.2.4 Business Segmentation by Revenue 2012 and 201321.2.5 Sales by Geography21.2.6 Business Strategy21.2.7 Key Information21.2.8 SWOT Analysis21.2.9 Strengths21.2.10 Weaknesses21.2.11 Opportunities21.2.12 Threats21.3 Novartis21.3.1 Key Facts21.3.2 Business Overview21.3.3 Business Segmentation by Revenue 201321.3.4 Business Segmentation by Revenue 2012 and 201321.3.5 Sales by Geography21.3.6 Business Strategy21.3.7 Key Developments21.3.8 SWOT Analysis21.3.9 Strengths21.3.10 Weaknesses21.3.11 Opportunities21.3.12 Threats21.4 Regeneron Pharmaceuticals21.4.1 Key Facts21.4.2 Business Overview21.4.3 Product Segmentation21.4.4 Revenue Product Segmentation21.4.5 Business Strategy21.4.6 Key Information21.4.7 SWOT Analysis21.4.8 Strengths21.4.9 Weaknesses21.4.10 Opportunities21.4.11 Threats22. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research MethodologyExhibit 2: Global Retinal Vein Occlusion Market 2013-2018 (US$ million)Exhibit 3: Pipeline Portfolio of the Drugs for the Treatment of Retinal Vein OcclusionExhibit 4: Global Retinal Vein Occlusion Market by Type of TherapyExhibit 5: Global Retinal Vein Occlusion Market by Route of AdministrationExhibit 6: Global Retinal Vein Occlusion Market by Dosage FormsExhibit 7: Global Retinal Vein Occlusion Market by Geographical SegmentationExhibit 8: Global Retinal Vein Occlusion Market Share Analysis 2013Exhibit 9: Product-wise Revenue Share in Global Retinal Vein Occlusion Market 2013Exhibit 10: Bayer AG: Business Segmentation 2013Exhibit 11: Bayer AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)Exhibit 12: Bayer AG: Sales by Geography 2013Exhibit 13: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013Exhibit 14: F. Hoffmann-La Roche Ltd: Business Segmentation by Revenue 2012 and 2013Exhibit 15: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Pharmaceuticals Division)Exhibit 16: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Diagnostics Division)Exhibit 17: Novartis AG: Business Segmentation by Revenue 2013Exhibit 18: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)Exhibit 19: Novartis AG: Sales by Geography 2013Exhibit 20: Regeneron Pharmaceuticals Inc.: Product SegmentationExhibit 21: Regeneron Pharmaceuticals Inc.: Revenue Product Segmentation 2013
Read the full report:Global Retinal Vein Occlusion Market 2014-2018
https://www.reportbuyer.com/product/2255167/Global-Retinal-Vein-Occlusion-Market-2014-2018.html
For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
SOURCE ReportBuyer
